Planet Labs PBC Beats Q1 Estimates with 42% Revenue Growth, Strong Backlog, and Positive FY27 Adjusted EBITDA Outlook
Summary
Planet Labs PBC exceeded Q1 revenue and EPS estimates, reporting 42% year-over-year revenue growth and strong increases in RPOs and backlog, while also guiding for positive Adjusted EBITDA for the full fiscal year.
Key Events
-
Strong Q1 Financial Beat
Reported Q1 FY27 revenue of $94.2 million, a 42% increase year-over-year, and non-GAAP EPS of ($0.03), both exceeding analyst estimates of $90 million and ($0.04) respectively.
-
Accelerating Growth Metrics
Remaining Performance Obligations (RPOs) surged 81% year-over-year to $816 million, and total backlog grew 72% year-over-year to over $906 million, indicating robust future revenue.
-
Robust Balance Sheet
Ended the quarter with $731 million in cash, cash equivalents, and short-term investments, a 223% increase year-over-year, significantly strengthened by $108 million from public warrant exercises.
-
Path to Profitability
Guided for positive Adjusted EBITDA in Q2 FY27 ($0-$5 million) and for the full fiscal year 2027 ($0-$10 million), signaling a clear trajectory towards operational profitability.
Analysis
Planet Labs PBC reported stronger-than-expected Q1 fiscal year 2027 results, surpassing analyst estimates for both revenue and non-GAAP EPS. The company demonstrated significant operational momentum with 42% year-over-year revenue growth and substantial increases in Remaining Performance Obligations (RPOs) and total backlog. A robust cash position, bolstered by recent warrant redemptions, provides strong financial flexibility. The company also provided positive guidance for Adjusted EBITDA, signaling a clear path to profitability for the current fiscal year. Multiple new and renewed contracts, coupled with advancements in satellite technology and AI products, underscore strong demand and innovation.
At the time of this filing, PL was trading at $42.83 on NYSE in the Manufacturing sector, with a market capitalization of approximately $15.5B. The 52-week trading range was $3.78 to $51.76. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.